Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Achieve Life Sciences Inc (ACHV)
NASDAQ:ACHV
RESEARCH TOOLSreports
ACHV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.84 - $5.59
Previous CloseN/A
Volume131.37K
Average Volume (3M)309.10K
Market Cap
$113.14M
Enterprise Value$129.78M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Mar 13, 2025EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.13
Shares Outstanding34,389,946
10 Day Avg. Volume243,756
30 Day Avg. Volume309,095
Standard Deviation0.24
R-Squared0.13
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.70
P/FCF Ratio0.00
Enterprise Value/Market Cap1.15
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-569.20
Enterprise Value/Ebitda-4.33
Forecast
1Y Price Target
$14.00Price Target Upside334.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Achieve Life Sciences News
PremiumCompany Announcements
Achieve Life Sciences Announces Board of Directors Changes
PremiumCompany Announcements
Achieve Life Sciences Appoints Mark K. Oki as CFO
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceACHV ended 3Q24 with a cash position of $42.9 million, which the company estimates will be sufficient to fund operations into 2H25.
Product EffectivenessCytisinicline was effective and well-tolerated in helping e-cigarette users stop using nicotine when combined with behavioral support.
Regulatory ApprovalFavorable end-of-Phase II meeting with the FDA clears the path for a significant vaping cessation opportunity.
Bears Say
Clinical Trial ProgressThe trial will assess safety, adherence to treatment, and other patient-reported outcomes, which is crucial for the success of the drug approval process.
Market PerceptionThe market is believed to be dramatically underestimating the commercial potential of cytisinicline, reinforcing the Buy rating and $20 price target.
Partnership StrategyThe company is no longer relying solely on finding a larger partner to commercialize its product, which allows ACHV to negotiate from a position of strength.
---
Ownership Overview
10.47% Insiders
14.43% Mutual Funds
16.07% Other Institutional Investors
49.76% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACHV FAQ
What was Achieve Life Sciences Inc’s price range in the past 12 months?
Achieve Life Sciences Inc lowest stock price was $2.84 and its highest was $5.59 in the past 12 months.
What is Achieve Life Sciences Inc’s market cap?
Achieve Life Sciences Inc’s market cap is $113.14M.
When is Achieve Life Sciences Inc’s upcoming earnings report date?
Achieve Life Sciences Inc’s upcoming earnings report date is Mar 13, 2025 which is in 20 days.
How were Achieve Life Sciences Inc’s earnings last quarter?
Achieve Life Sciences Inc released its earnings results on Nov 07, 2024. The company reported -$0.36 earnings per share for the quarter, missing the consensus estimate of -$0.272 by -$0.088.
Is Achieve Life Sciences Inc overvalued?
According to Wall Street analysts Achieve Life Sciences Inc’s price is currently Undervalued.
Does Achieve Life Sciences Inc pay dividends?
Achieve Life Sciences Inc does not currently pay dividends.
What is Achieve Life Sciences Inc’s EPS estimate?
Achieve Life Sciences Inc’s EPS estimate is -0.34.
How many shares outstanding does Achieve Life Sciences Inc have?
Achieve Life Sciences Inc has 34,389,946 shares outstanding.
What happened to Achieve Life Sciences Inc’s price movement after its last earnings report?
Achieve Life Sciences Inc reported an EPS of -$0.36 in its last earnings report, missing expectations of -$0.272. Following the earnings report the stock price went down -7.4%.
Which hedge fund is a major shareholder of Achieve Life Sciences Inc?
Currently, no hedge funds are holding shares in ACHV
---
Achieve Life Sciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.00 (334.78% Upside)
$14.00 (334.78% Upside)
Blogger Sentiment
Bullish
ACHV Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Positive
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 5.0%
Last 30 Days ▲ 5.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.69%
12-Months-Change
Fundamentals
Return on Equity
-186.03%
Trailing 12-Months
Asset Growth
96.89%
Trailing 12-Months
Company Description
Achieve Life Sciences Inc
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products, cytisine, is a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
---
ACHV Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress with the breakthrough therapy designation for vaping cessation, successful enrollment in the ORCA-OL trial, and a strong cash position supporting future growth. However, the increased net loss and executive restructure costs were notable challenges.Read More>---
ACHV Stock 12 Month Forecast
Average Price Target
$14.00
▲(334.78% Upside)
Technical Analysis
Best Analysts Covering ACHV
1 Year
1 Year Success Rate
6/13 ratings generated profit
1 Year Average Return
-0.84%
reiterated a buy rating last month
Copying Francois Brisebois's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of -0.84% per trade.
---